Evidence map›Paper›PMID 35419562›Full record

ArticleFrontiers in genome editing2022

A Single Transcript Knockdown-Replacement Strategy Employing 5' UTR Secondary Structures to Precisely Titrate Rescue Protein Translation.

Matthew M Millette, Elizabeth D Holland, Tanner J Tenpas, Erik W Dent

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genome editing, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Matthew M MilletteDepartment of Neuroscience, School of Medicine and Public Health, University of Wisconsin, Madison, WI, United States.
Elizabeth D HollandNeuroscience Training Program, University of Wisconsin, Madison, WI, United States.
Tanner J TenpasDepartment of Neuroscience, School of Medicine and Public Health, University of Wisconsin, Madison, WI, United States.
Erik W DentDepartment of Neuroscience, School of Medicine and Public Health, University of Wisconsin, Madison, WI, United States.
University of Wisconsin–Madison · US

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Neuroscience Training ProgramT32NS105602 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI Ari Rosenberg · 2019 to 2026
$2.5M
Microtubule Dynamics in Neuronal DendritesR01NS098372 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI DENT, ERIK W · 2016 to 2020
$1.8M
NCATS NIH HHS UL1 TR002373NINDS NIH HHS R01 NS098372NINDS NIH HHS T32 NS105602
6 · The paper itself

Abstract

One overarching goal of gene therapy is the replacement of faulty genes with functional ones. A significant hurdle is presented by the fact that under- or over-expression of a protein may cause disease as readily as coding mutations. There is a clear and present need for pipelines to translate experimentally validated gene therapy strategies to clinical application. To address this we developed a modular, single-transgene expression system for replacing target genes with physiologically expressed variants. In order to accomplish this, we first designed a range of 5' UTR "attenuator" sequences which predictably diminish translation of the paired gene. These sequences provide wide general utility by allowing control over translation from high expression, ubiquitous promoters. Importantly, we demonstrate that this permits an entirely novel knockdown and rescue application by pairing microRNA-adapted shRNAs alongside their respective replacement gene on a single transcript. A noteworthy candidate for this corrective approach is the degenerative and uniformly fatal motor neuron disease ALS. A strong proportion of non-idiopathic ALS cases are caused by varied mutations to the SOD1 gene, and as clinical trials to treat ALS are being initiated, it is important to consider that loss-of-function mechanisms contribute to its pathology as strongly as any other factor. As a generalized approach to treat monogenic diseases caused by heterogeneous mutations, we demonstrate complete and predictable control over replacement of SOD1 in stable cell lines by varying the strength of attenuators.

Indexed as

amyotrophic lateral sclerosisgene therapyhairpinknockdown-rescueprotein translationRNAiUTR

Identifiers

PMID35419562
PMCPMC8995503
OpenAlexW4220976757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.